George C Tsokos

List of Publications by Year in descending order

527 papers	27,279 citations	7568 77 h-index	13379 130 g-index
569 all docs	569 docs citations	569 times ranked	21315 citing authors

#	Article	IF	Citations
1	Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Current Opinion in Rheumatology, 2023, 35, 107-116.	4.3	16
2	Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis. Rheumatology, 2023, 62, 861-871.	1.9	5
3	Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study. Journal of Rheumatology, 2022, 49, 380-387.	2.0	14
4	Tissue resident cell processes determine organ damage in systemic lupus erythematosus. Clinical Immunology, 2022, 234, 108919.	3.2	1
5	Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukinâ€2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 1204-1210.	5.6	8
6	Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus. Frontiers in Immunology, 2022, 13, 855812.	4.8	1
7	Mitochondria in the Pathogenesis of Systemic Lupus Erythematosus. Current Rheumatology Reports, 2022, 24, 88-95.	4.7	18
8	Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. Translational Research, 2022, 245, 18-29.	5.0	8
9	The global burden of heterogeneity of lupus erythematosus interventional trials. Journal of Autoimmunity, 2022, 128, 102798.	6.5	2
10	The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription. , 2022, 19, 738-750.		12
11	Therapeutic potential of interleukin-2 in autoimmune diseases. Trends in Molecular Medicine, 2022, 28, 596-612.	6.7	22
12	Melanocyte-secreted fibromodulin constrains skin inflammation in mice injected with lupus serum. Clinical Immunology, 2022, , 109055.	3.2	3
13	Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial. Journal of Autoimmunity, 2022, 130, 102844.	6.5	52
14	CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Science Advances, 2022, 8, .	10.3	21
15	Lymphocytes in the neighborhood: good or bad for the kidney?. Journal of Clinical Investigation, 2022, 132, .	8.2	2
16	Ikaros, Aiolos and other moving targets to treat SLE. Nature Reviews Rheumatology, 2022, 18, 499-500.	8.0	2
17	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury. American Journal of Transplantation, 2021, 21, 148-160.	4.7	13
18	Suppression of Serum Interferonâ€Î³ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2021, 73, 472-477.	5.6	18

#	Article	IF	Citations
19	IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. Clinical Reviews in Allergy and Immunology, 2021, 60, 31-45.	6.5	14
20	An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2021, 73, 232-243.	5.6	115
21	TNF-Î± Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-Î± Production and Enhancing T Cell Activation. Journal of Immunology, 2021, 206, 785-796.	0.8	33
22	T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: an Update. Current Rheumatology Reports, 2021, 23, 12.	4.7	52
23	Amino Acid Metabolism in Lupus. Frontiers in Immunology, 2021, 12, 623844.	4.8	12
24	Skinâ€“kidney crosstalk in SLE. Nature Reviews Rheumatology, 2021, 17, 253-254.	8.0	7
25	Criteria, criteria all around but not an insight into lupus. Rheumatology, 2021, 60, 3037-3038.	1.9	9
26	The Regulatory Subunit PPP2R2A of PP2A Enhances Th1 and Th17 Differentiation through Activation of the GEF-H1/RhoA/ROCK Signaling Pathway. Journal of Immunology, 2021, 206, 1719-1728.	0.8	22
27	ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-Î²1. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
28	Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clinical Immunology, 2021, 225, 108680.	3.2	23
29	Skeletal muscle heme oxygenase-1 activity regulates aerobic capacity. Cell Reports, 2021, 35, 109018.	6.4	18
30	Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis. JCI Insight, 2021, 6, .	5.0	34
31	Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19. Clinical Immunology, 2021, 226, 108716.	3.2	41
32	IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. Journal of Clinical Investigation, 2021, 131, .	8.2	33
33	Cyclic AMP Response Element Modulator-Î± Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis. Journal of Immunology, 2021, 207, 55-64.	0.8	4
34	The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update. Current Opinion in Rheumatology, 2021, 33, 586-591.	4.3	35
35	Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. Nature Communications, 2021, 12, 4977.	12.8	73
36	Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19. Clinical Immunology, 2021, 229, 108795.	3.2	16

#	Article	IF	Citations
37	Glutathione peroxidase 4â€“regulated neutrophil ferroptosis induces systemic autoimmunity. Nature Immunology, 2021, 22, 1107-1117.	14.5	185
38	Reactive oxygen species: The Yin and Yang in (auto-)immunity. Autoimmunity Reviews, 2021, 20, 102869.	5.8	20
39	Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nature Biomedical Engineering, 2021, 5, 1288-1305.	22.5	47
40	New therapeutic approaches in systemic lupus erythematosus. Current Opinion in Rheumatology, 2021, 33, 181-189.	4.3	5
41	Double-negative T cells in autoimmune diseases. Current Opinion in Rheumatology, 2021, 33, 163-172.	4.3	34
42	Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmunity Reviews, 2021, 20, 102980.	5.8	35
43	Interleukin-2 and regulatory T cells in rheumatic diseases. Nature Reviews Rheumatology, 2021, 17, 749-766.	8.0	59
44	Shortage of aspartate in mitochondria fuels arthritis. Nature Immunology, 2021, 22, 1474-1476.	14.5	1
45	Kidney-Draining Lymph Node Fibrosis Following Unilateral Ureteral Obstruction. Frontiers in Immunology, 2021, 12, 768412.	4.8	2
46	The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8ÂT Cell Function and Identifies Patients with SLE Prone to Infections. Cell Reports, 2020, 30, 112-123.e4.	6.4	102
47	Animal Models: Systemic Autoimmune Diseases. , 2020, , 533-551.		1
48	Metabolic control of T cells in autoimmunity. Current Opinion in Rheumatology, 2020, 32, 192-199.	4.3	15
49	Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase <scp>II</scp> Multicenter, Prospective, Randomized, Doubleâ€Blind, Placeboâ€Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 761-768.	5.6	38
50	Complement Deposition on the Surface of RBC After Trauma Serves a Biomarker of Moderate Trauma Severity: A Prospective Study. Shock, 2020, 53, 16-23.	2.1	15
51	Curb complement to cure COVID-19. Clinical Immunology, 2020, 221, 108603.	3.2	12
52	Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nature Communications, 2020, 11, 6149.	12.8	71
53	O9â€…Reduction of interferon-Î³ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE. , 2020, , .		0
54	T Lymphocytes Cash Their Value in Clinical Medicine. Trends in Molecular Medicine, 2020, 26, 800-802.	6.7	2

#	Article	IF	Citations
55	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Reports Medicine, 2020, 1, 100137.	6.5	56
56	Autoimmunity and organ damage in systemic lupus erythematosus. Nature Immunology, 2020, 21, 605-614.	14.5	294
57	Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. Nature Communications, 2020, 11, 2859.	12.8	59
58	Cellâ€Derived Extracellular Matrixâ€Rich Biomimetic Substrate Supports Podocyte Proliferation, Differentiation, and Maintenance of Native Phenotype. Advanced Functional Materials, 2020, 30, 1908752.	14.9	54
59	TCR-Î±/Î² CD4â˜ CD8â˜ double negative T cells arise from CD8+ T cells. Journal of Leukocyte Biology, 2020, 108, 851-857.	3.3	18
60	Notch notches lupus. Kidney International, 2020, 97, 251-253.	5.2	1
61	T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nature Reviews Rheumatology, 2020, 16, 100-112.	8.0	174
62	Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 624971.	4.8	26
63	Serine/threonine phosphatase PP2A is essential for optimal B cell function. JCI Insight, 2020, 5, .	5.0	9
64	PPP2R2D suppresses IL-2 production and Treg function. JCI Insight, 2020, 5, .	5.0	14
65	Protein phosphatase 2A B55Î² limits CD8+ T cell lifespan following cytokine withdrawal. Journal of Clinical Investigation, 2020, 130, 5989-6004.	8.2	5
66	Cancer immunosurveillance by CD8 T cells. F1000Research, 2020, 9, 80.	1.6	11
67	T cell Metabolism in Lupus. Immunometabolism, 2020, 2, .	1.6	23
68	Signaling Lymphocytic Activation Molecule Family Member 1 Engagement Inhibits T Cellâ€“B Cell Interaction and Diminishes Interleukinâ€6 Production and Plasmablast Differentiation in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 99-108.	5.6	17
69	SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunology Research, 2019, 7, 1485-1496.	3.4	34
70	Complement and coagulation cascades in trauma. Acute Medicine & Surgery, 2019, 6, 329-335.	1.2	31
71	cAMP Response Element Modulator Î± Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus. Journal of Immunology, 2019, 203, 2807-2816.	0.8	21
72	Hyaluronic Acid Synthesis Contributes to Tissue Damage in Systemic Lupus Erythematosus. Frontiers in Immunology, 2019, 10, 2172.	4.8	12

#	Article	IF	Citations
73	Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 199.	4.8	11
74	Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupusâ€like Disease in <scp>MRL</scp>/lpr Mice and Experimental Autoimmune Encephalomyelitis. Arthritis and Rheumatology, 2019, 71, 1869-1878.	5.6	66
75	CD25 and Protein Phosphatase 2A Cooperate to Enhance IL-2R Signaling in Human Regulatory T Cells. Journal of Immunology, 2019, 203, 93-104.	0.8	13
76	T Cells in Autoimmune Diseases. , 2019, , 29-36.		0
77	The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. Expert Review of Clinical Immunology, 2019, 15, 629-637.	3.0	39
78	OP0278â€...BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		1
79	OP0041â€...MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY. , 2019, , .		2
80	SP0083â€...MOLECULAR AND METABOLIC EVENTS WHICH UNDERWRITE T CELL PHENOTYPES IN AUTOIMMUNITY. , 2019, , .		0
81	201â€...Ustekinumab targets a novel mechanism of action to treat patients with systemic lupus erythematosus. , 2019, , .		0
82	251â€...Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. , 2019, , .		2
83	SNPs talk to genes using landlines: long-range chromatin interactions link genetic risk with epigenetic patterns in Takayasu arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1293-1295.	0.9	1
84	The immune podocyte. Current Opinion in Rheumatology, 2019, 31, 167-174.	4.3	36
85	T Cells. , 2019, , 116-124.		0
86	Signaling lymphocyte activation molecule family in systemic lupus erythematosus. Clinical Immunology, 2019, 204, 57-63.	3.2	10
87	A new checkpoint in lupus. Journal of Allergy and Clinical Immunology, 2019, 143, 1351-1352.	2.9	1
88	PP2A enables IL-2 signaling by preserving IL-2RÎ² chain expression during Treg development. JCI Insight, 2019, 4, .	5.0	18
89	Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight, 2019, 4, .	5.0	79
90	Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity. Journal of Clinical Investigation, 2019, 129, 5411-5423.	8.2	59

#	Article	IF	Citations
91	TARGETING TARGETED TREATMENT FOR IMMUNE AND NON-IMMUNE KIDNEY DISEASES. Transactions of the American Clinical and Climatological Association, 2019, 130, 88-99.	0.5	1
92	Transcriptional factor ICER promotes glutaminolysis and the generation of Th17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2478-2483.	7.1	79
93	Downregulation of CD3Î¶ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype. Journal of Immunology, 2018, 200, 3077-3086.	0.8	12
94	The serine/threonine protein phosphatase 2A controls autoimmunity. Clinical Immunology, 2018, 186, 38-42.	3.2	40
95	Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Current Opinion in Rheumatology, 2018, 30, 222-228.	4.3	39
96	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet, The, 2018, 392, 1330-1339.	13.7	244
97	Genome-Wide Association Study Reveals Genetic Link between Diarrhea-Associated Entamoeba histolytica Infection and Inflammatory Bowel Disease. MBio, 2018, 9, .	4.1	23
98	Regulatory T cells in the treatment of disease. Nature Reviews Drug Discovery, 2018, 17, 823-844.	46.4	224
99	Calcium/Calmodulin Kinase IV Controls the Function of Both T Cells and Kidney Resident Cells. Frontiers in Immunology, 2018, 9, 2113.	4.8	25
100	Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9288-9293.	7.1	51
101	New insights into the role of renal resident cells in the pathogenesis of lupus nephritis. Korean Journal of Internal Medicine, 2018, 33, 284-289.	1.7	24
102	Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 786.	4.8	56
103	Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1088.	4.8	170
104	Decreased Expression of Serine/Arginineâ€Rich Splicing Factor 1 in T Cells From Patients With Active Systemic Lupus Erythematosus Accounts for Reduced Expression of RasGRP1 and DNA Methyltransferase 1. Arthritis and Rheumatology, 2018, 70, 2046-2056.	5.6	20
105	Precision DNA demethylation ameliorates disease in lupus-prone mice. JCI Insight, 2018, 3, .	5.0	42
106	CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. Journal of Clinical Investigation, 2018, 128, 3445-3459.	8.2	80
107	T cells and IL-17 in lupus nephritis. Clinical Immunology, 2017, 185, 95-99.	3.2	89
108	Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 1035-1044.	5.6	63

#	Article	IF	Citations
109	Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice. Journal of Immunology, 2017, 198, 1846-1854.	0.8	21
110	CD74 Deficiency Mitigates Systemic Lupus Erythematosusâ€“like Autoimmunity and Pathological Findings in Mice. Journal of Immunology, 2017, 198, 2568-2577.	0.8	13
111	Downregulation of miR-200a-3p, Targeting CtBP2 Complex, Is Involved in the Hypoproduction of IL-2 in Systemic Lupus Erythematosusâ€“Derived T Cells. Journal of Immunology, 2017, 198, 4268-4276.	0.8	37
112	Immune cell signaling in autoimmune diseases. Clinical Immunology, 2017, 181, 1-8.	3.2	6
113	Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends in Molecular Medicine, 2017, 23, 615-635.	6.7	328
114	Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature, 2017, 546, 539-543.	27.8	173
115	T cells and autoimmune kidney disease. Nature Reviews Nephrology, 2017, 13, 329-343.	9.6	106
116	Intracellular Activation of Complement 3 Is Responsible for Intestinal Tissue Damage during Mesenteric Ischemia. Journal of Immunology, 2017, 198, 788-797.	0.8	68
117	Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukinâ€2. Arthritis and Rheumatology, 2017, 69, 808-813.	5.6	51
118	Fat T cells go to the joint. Nature Immunology, 2017, 18, 955-956.	14.5	2
119	IL-17A Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion Injury. Journal of Immunology, 2017, 199, 2921-2929.	0.8	14
120	IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus. Journal of Immunology, 2017, 199, 903-910.	0.8	83
121	DNA methylation in systemic lupus erythematosus. Epigenomics, 2017, 9, 505-525.	2.1	86
122	SLE-Associated Defects Promote Altered T Cell Function. Critical Reviews in Immunology, 2017, 37, 39-58.	0.5	21
123	Principles of Signaling. , 2017, , 408-417.		0
124	C3a Enhances the Formation of Intestinal Organoids through C3aR1. Frontiers in Immunology, 2017, 8, 1046.	4.8	24
125	Neutrophil FcÎ³RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. Journal of Clinical Investigation, 2017, 127, 3810-3826.	8.2	48
126	Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus. PLoS ONE, 2017, 12, e0186073.	2.5	27

#	Article	IF	Citations
127	Aneurysm of the ascending aorta in systemic lupus erythematosus: Case report and review of the literature. European Journal of Rheumatology, 2017, 4, 133-135.	0.6	8
128	Targeting Syk in Autoimmune Rheumatic Diseases. Frontiers in Immunology, 2016, 7, 78.	4.8	62
129	Calcium/CalmodulinâEDependent Kinase IV Facilitates the Recruitment of InterleukinâE17âE“Producing Cells to Target Organs Through the CCR6/CCL20 Axis in Th17 CellâE“Driven Inflammatory Diseases. Arthritis and Rheumatology, 2016, 68, 1981-1988.	5.6	41
130	N-WASP is required for B-cellâE“mediated autoimmunity in Wiskott-Aldrich syndrome. Blood, 2016, 127, 216-220.	1.4	24
131	Low-Dose IL-2 in the Treatment of Lupus. Current Rheumatology Reports, 2016, 18, 68.	4.7	37
132	Engagement of SLAMF3 enhances CD4 ⁺ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9321-9326.	7.1	30
133	Empowering Regulatory T Cells in Autoimmunity. Trends in Molecular Medicine, 2016, 22, 784-797.	6.7	49
134	The role of Syk in cutaneous lupus erythematosus. Experimental Dermatology, 2016, 25, 674-675.	2.9	7
135	What rheumatologists need to know about innate lymphocytes. Nature Reviews Rheumatology, 2016, 12, 658-668.	8.0	10
136	New insights into the immunopathogenesis of systemic lupus erythematosus. Nature Reviews Rheumatology, 2016, 12, 716-730.	8.0	909
137	ICER is requisite for Th17 differentiation. Nature Communications, 2016, 7, 12993.	12.8	64
138	T cells in Systemic Lupus Erythematosus. Current Opinion in Immunology, 2016, 43, 32-38.	5.5	150
139	Metabolic control of arthritis: Switch pathways to treat. Science Translational Medicine, 2016, 8, 331fs8.	12.4	14
140	Complement Activation in Trauma Patients Alters Platelet Function. Shock, 2016, 46, 83-88.	2.1	27
141	C1 Inhibitor Limits Organ Injury and Prolongs Survival in Swine Subjected to Battlefield Simulated Injury. Shock, 2016, 46, 177-188.	2.1	16
142	Pin1â€Targeted Therapy for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 2503-2513.	5.6	22
143	Proâ€inflammatory selfâ€reactive TÂcells are found within murine TCRâ€Î±Î²⁺CD4^{â^'}CD8^{â^'}PDâ€1⁺ cells. European Journal of Immunology, 2016, 46, 1383-1391.	2.9	36
144	Lupus Nephritis IgG Induction of Calcium/CalmodulinâEDependent Protein Kinase IV Expression in Podocytes and Alteration of Their Function. Arthritis and Rheumatology, 2016, 68, 944-952.	5.6	50

#	Article	IF	Citations
145	Decreased SAP Expression in T Cells from Patients with Systemic Lupus Erythematosus Contributes to Early Signaling Abnormalities and Reduced IL-2 Production. Journal of Immunology, 2016, 196, 4915-4924.	0.8	14
146	Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4â€“Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 164-173.	5.6	53
147	Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Annals of the Rheumatic Diseases, 2016, 75, 2014-2021.	0.9	200
148	Phosphatase PP2A is requisite for the function of regulatory T cells. Nature Immunology, 2016, 17, 556-564.	14.5	191
149	Cellular and metabolic requirements of effector T cells. Nature Reviews Rheumatology, 2016, 12, 74-76.	8.0	11
150	Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. Journal of Clinical Investigation, 2016, 126, 4219-4236.	8.2	56
151	Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. Journal of Clinical Investigation, 2016, 126, 2077-2092.	8.2	56
152	T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. Journal of Clinical Investigation, 2015, 125, 2220-2227.	8.2	185
153	Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Clinical Immunology, 2015, 160, 286-291.	3.2	25
154	Update on the role of Interleukin 17 in rheumatologic autoimmune diseases. Cytokine, 2015, 75, 207-215.	3.2	28
155	Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. Journal of Immunology, 2015, 195, 5533-5537.	0.8	53
156	Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. Journal of Allergy and Clinical Immunology, 2015, 135, 272-273.	2.9	30
157	T Cells and Autoimmunity. , 2015, , 85-108.		0
158	A quantitative lateral flow assay to detect complement activation in blood. Analytical Biochemistry, 2015, 477, 78-85.	2.4	45
159	Pathogenesis and targeted treatment of skin injury in SLE. Nature Reviews Rheumatology, 2015, 11, 663-669.	8.0	51
160	Target It All Right, But Do Not Forget the Torchbearer. Circulation, 2015, 131, 1153-1155.	1.6	1
161	Programmed Cell Death 1 and Helios Distinguish TCR-Î±Î²+ Double-Negative (CD4âˆ’CD8âˆ’) T Cells That Derive from Self-Reactive CD8 T Cells. Journal of Immunology, 2015, 194, 4207-4214.	0.8	53
162	Serine Arginine-Rich Splicing Factor 1 (SRSF1) Contributes to the Transcriptional Activation of CD3Î¶ in Human T Cells. PLoS ONE, 2015, 10, e0131073.	2.5	13

#	Article	IF	Citations
163	T Cell Transcriptomes Describe Patient Subtypes in Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0141171.	2.5	44
164	Pathogenesis of lupus. , 2015, , 1082-1087.		0
165	Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model. Clinical and Experimental Rheumatology, 2015, 33, S15-22.	0.8	12
166	Lupus-Prone Mice Fail to Raise Antigen-Specific T Cell Responses to Intracellular Infection. PLoS ONE, 2014, 9, e111382.	2.5	21
167	IL-2 Protects Lupus-Prone Mice from Multiple End-Organ Damage by Limiting CD4â^'CD8â^' IL-17â€"Producing T Cells. Journal of Immunology, 2014, 193, 2168-2177.	0.8	105
168	KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3⁺regulatory T cells in MRL/lprmice. Autoimmunity, 2014, 47, 445-450.	2.6	60
169	A114: Methylprednisolone-Induced Inhibition of miR-155 Expression Increases SOCS1-Driven Suppression of Cytokine Signaling. Arthritis and Rheumatology, 2014, 66, S151-S151.	5.6	9
170	cAMP Responsive Element Modulator (CREM) Î± Mediates Chromatin Remodeling of CD8 during the Generation of CD3+CD4â^'CD8â^' T Cells. Journal of Biological Chemistry, 2014, 289, 2361-2370.	3.4	66
171	Engagement of SLAMF2/CD48 Prolongs the Time Frame of Effective T Cell Activation by Supporting Mature Dendritic Cell Survival. Journal of Immunology, 2014, 192, 4436-4442.	0.8	17
172	The role of T cells in systemic lupus erythematosus. Current Opinion in Rheumatology, 2014, 26, 493-501.	4.3	58
173	Systemic Lupus Erythematosus, Animal Models. , 2014, , 1134-1141.		0
174	A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clinical Immunology, 2014, 150, 192-200.	3.2	33
175	Nephritic Factor Autoantibodies. , 2014, , 561-565.		2
176	Stat3 promotes IL-10 expression in lupus T cells through trans- activation and chromatin remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13457-13462.	7.1	148
177	Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity, 2014, 47, 234-241.	2.6	59
178	Ubiquitination Regulates Expression of the Serine/Arginine-rich Splicing Factor 1 (SRSF1) in Normal and Systemic Lupus Erythematosus (SLE) T Cells. Journal of Biological Chemistry, 2014, 289, 4126-4134.	3.4	39
179	Transcription factor Ikaros Represses Protein Phosphatase 2A (PP2A) Expression through an Intronic Binding Site. Journal of Biological Chemistry, 2014, 289, 13751-13757.	3.4	20
180	A serine/threonine phosphatase, PP2A, controls autoimmunity. Arthritis Research and Therapy, 2014, 16, A30.	3.5	0

#	Article	IF	Citations
181	Monogenic lupus. International Journal of Clinical Rheumatology, 2014, 9, 543-546.	0.3	4
182	C4d Deposits on the Surface of RBCs in Trauma Patients and Interferes With Their Function*. Critical Care Medicine, 2014, 42, e364-e372.	0.9	24
183	CaMK4-dependent activation of AKT/mTOR and CREM-Î± underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 2014, 124, 2234-2245.	8.2	185
184	Low-dose Interleukin-2 in the Treatment of Autoimmune Disease. Oncology & Hematology Review, 2014, 10, 157.	0.2	6
185	cAMP responsive element modulator: a critical regulator of cytokine production. Trends in Molecular Medicine, 2013, 19, 262-269.	6.7	77
186	Human Complement Receptor Type 1/CD35 Is an Epstein-Barr Virus Receptor. Cell Reports, 2013, 3, 371-385.	6.4	113
187	Decay-accelerating factor limits hemorrhage-instigated tissue injury and improves resuscitation clinical parameters. Journal of Surgical Research, 2013, 179, 153-167.	1.6	22
188	Bridging the gap between autoinflammation and autoimmunity. Clinical Immunology, 2013, 147, 151-154.	3.2	19
189	Expansion of an osteopontinâ€expressing T follicular helper cell subset correlates with autoimmunity inB6.Sle1bmice and is suppressed by the H1â€isoform of the Slamf6 receptor. FASEB Journal, 2013, 27, 3123-3131.	0.5	21
190	Gene-function studies in systemic lupus erythematosus. Nature Reviews Rheumatology, 2013, 9, 476-484.	8.0	99
191	T Cells. , 2013, , 96-103.		2
192	Brief Report: Increased expression of a short splice variant of CTLAâ€4 exacerbates lupus in MRL/lpr mice. Arthritis and Rheumatism, 2013, 65, 764-769.	6.7	7
193	Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice. BioMed Research International, 2013, 2013, 1-5.	1.9	46
194	Glucocorticoids Suppress T Cell Function by Upâ€Regulating MicroRNAâ€98. Arthritis and Rheumatism, 2013, 65, 1882-1890.	6.7	52
195	Complement depletion protects lupus-prone mice from ischemia-reperfusion-initiated organ injury. American Journal of Physiology - Renal Physiology, 2013, 304, G283-G292.	3.4	3
196	New therapeutics in systemic lupus erythematosus. Current Opinion in Rheumatology, 2013, 25, 297-303.	4.3	22
197	Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling. Journal of Biological Chemistry, 2013, 288, 26775-26784.	3.4	77
198	Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in theFas^{lpr}mouse. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20194-20199.	7.1	83

#	Article	IF	Citations
199	T Cell CD3Î¶ Deficiency Enables Multiorgan Tissue Inflammation. Journal of Immunology, 2013, 191, 3563-3567.	0.8	25
200	cAMP-responsive Element Modulator Î± (CREMÎ±) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3+CD4â^'CD8â^' T Cells in Health and Disease. Journal of Biological Chemistry, 2013, 288, 31880-31887.	3.4	53
201	R-spondin3 prevents mesenteric ischemia/reperfusion-induced tissue damage by tightening endothelium and preventing vascular leakage. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14348-14353.	7.1	36
202	Platelets, complement and tissue inflammation. Autoimmunity, 2013, 46, 1-5.	2.6	15
203	The Catalytic Subunit of Protein Phosphatase 2A (PP2Ac) Promotes DNA Hypomethylation by Suppressing the Phosphorylated Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (ERK) Kinase (MEK)/Phosphorylated ERK/DNMT1 Protein Pathway in T-cells from Controls and Systemic Lupus Erythematosus Patients. Journal of Biological Chemistry, 2013, 288, 21936-21944.	3.4	91
204	Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1845-1850.	7.1	51
205	Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling. PLoS ONE, 2013, 8, e74550.	2.5	42
206	Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2012, 302, G1416-G1422.	3.4	10
207	Identification of Orch3, a Locus Controlling Dominant Resistance to Autoimmune Orchitis, as Kinesin Family Member 1C. PLoS Genetics, 2012, 8, e1003140.	3.5	13
208	cAMP response element modulator Î± controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16606-16611.	7.1	92
209	Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency. Journal of Immunology, 2012, 189, 3714-3723.	0.8	57
210	Increased Expression of SLAM Receptors SLAMF3 and SLAMF6 in Systemic Lupus Erythematosus T Lymphocytes Promotes Th17 Differentiation. Journal of Immunology, 2012, 188, 1206-1212.	0.8	65
211	cAMP-responsive Element Modulator Î± (CREMÎ±) Contributes to Decreased Notch-1 Expression in T Cells from Patients with Active Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 42525-42532.	3.4	44
212	cAMP-responsive Element Modulator Î± (CREMÎ±) Suppresses IL-17F Protein Expression in T Lymphocytes from Patients with Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 4715-4725.	3.4	61
213	CREMÎ± overexpression decreases IL-2 production, induces a TH17 phenotype and accelerates autoimmunity. Journal of Molecular Cell Biology, 2012, 4, 121-123.	3.3	34
214	c-Jun and Ets2 Proteins Regulate Expression of Spleen Tyrosine Kinase in T Cells. Journal of Biological Chemistry, 2012, 287, 11833-11841.	3.4	10
215	Cutting Edge: Protein Phosphatase 2A Confers Susceptibility to Autoimmune Disease through an IL-17â€“Dependent Mechanism. Journal of Immunology, 2012, 188, 3567-3571.	0.8	51
216	Cytokines in Systemic Lupus Erythematosus 2011. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-1.	3.0	3

#	Article	IF	Citations
217	Effects of C1 Inhibitor on Tissue Damage in a Porcine Model of Controlled Hemorrhage. Shock, 2012, 38, 82-91.	2.1	38
218	SAP expression in invariant NKT cells is required for cognate help to support B-cell responses. Blood, 2012, 120, 122-129.	1.4	33
219	Adhesion molecule expression precedes brain damages of lupus-prone mice and correlates with kidney pathology. Journal of Neuroimmunology, 2012, 252, 24-32.	2.3	17
220	B cellâ€“intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood, 2012, 119, 2819-2828.	1.4	99
221	Interleukinâ€2 in systemic autoimmunity hits the micro way. Arthritis and Rheumatism, 2012, 64, 3494-3497.	6.7	4
222	Platelets orchestrate remote tissue damage after mesenteric ischemia-reperfusion. American Journal of Physiology - Renal Physiology, 2012, 302, G888-G897.	3.4	26
223	Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus. Journal of Immunology, 2012, 189, 3490-3496.	0.8	91
224	Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus. Trends in Molecular Medicine, 2012, 18, 101-108.	6.7	82
225	CD3-T Cell Receptor Co-stimulation through SLAMF3 and SLAMF6 Receptors Enhances RORÎ³t Recruitment to the IL17A Promoter in Human T Lymphocytes. Journal of Biological Chemistry, 2012, 287, 38168-38177.	3.4	22
226	Platelet-Associated CD40/CD154 Mediates Remote Tissue Damage after Mesenteric Ischemia/Reperfusion Injury. PLoS ONE, 2012, 7, e32260.	2.5	24
227	The Role of Platelet Factor 4 in Local and Remote Tissue Damage in a Mouse Model of Mesenteric Ischemia/Reperfusion Injury. PLoS ONE, 2012, 7, e39934.	2.5	28
228	Estrogen Upregulates Cyclic AMP Response Element Modulator Î± Expression and Downregulates Interleukin-2 Production by Human T Lymphocytes. Molecular Medicine, 2012, 18, 370-378.	4.4	51
229	Treatment of systemic lupus erythematosus: new advances in targeted therapy. Annals of the New York Academy of Sciences, 2012, 1247, 138-152.	3.8	38
230	Why do women get lupus?. Clinical Immunology, 2012, 144, 53-56.	3.2	14
231	Excellence in Rheumatology 2012 25-28 January Madrid. International Journal of Rheumatic Diseases, 2012, 15, e17-e18.	1.9	0
232	CREMÎ± suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells. Arthritis and Rheumatism, 2012, 64, 799-807.	6.7	12
233	Methods and Protocols to Study T Cell Signaling Abnormalities in Human Systemic Lupus Erythematosus. Methods in Molecular Biology, 2012, 900, 25-60.	0.9	2
234	Cytosolic DNA-Activated Human Dendritic Cells Are Potent Activators of the Adaptive Immune Response. Journal of Immunology, 2011, 187, 1222-1234.	0.8	63

#	Article	IF	Citations
235	Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Research and Therapy, 2011, 13, 207.	3.5	157
236	The Dysregulation of Cytokine Networks in Systemic Lupus Erythematosus. Journal of Interferon and Cytokine Research, 2011, 31, 769-779.	1.2	120
237	Depletion of gut commensal bacteria attenuates intestinal ischemia/reperfusion injury. American Journal of Physiology - Renal Physiology, 2011, 301, G1020-G1030.	3.4	83
238	Systemic Lupus Erythematosus. New England Journal of Medicine, 2011, 365, 2110-2121.	27.0	2,265
239	Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferonâ€“mediated immunity. Nature Immunology, 2011, 12, 733-741.	14.5	76
240	SLAMF6-driven co-stimulation of human peripheral T cells is defective in SLE T cells. Autoimmunity, 2011, 44, 211-218.	2.6	37
241	Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends in Molecular Medicine, 2011, 17, 714-724.	6.7	154
242	A Novel Inhibitor of the Alternative Pathway of Complement Attenuates Intestinal Ischemia/Reperfusion-Induced Injury. Journal of Surgical Research, 2011, 167, e131-e136.	1.6	30
243	Decay-Accelerating Factor Attenuates C-Reactive Protein-Potentiated Tissue Injury After Mesenteric Ischemia/Reperfusion. Journal of Surgical Research, 2011, 167, e103-e115.	1.6	22
244	The Role of Interleukin-17 in Systemic Lupus Erythematosus. , 2011, , 391-400.		1
245	T-Cells and Systemic Lupus Erythematosus. , 2011, , 129-142.		0
246	Decay-Accelerating Factor Mitigates Controlled Hemorrhage-Instigated Intestinal and Lung Tissue Damage and Hyperkalemia in Swine. Journal of Trauma, 2011, 71, S151-S160.	2.3	15
247	Immunopathogenesis of ischemia/reperfusion-associated tissue damage. Clinical Immunology, 2011, 141, 3-14.	3.2	72
248	Towards the next generation of anti-TNF drugs. Clinical Immunology, 2011, 141, 231-235.	3.2	35
249	In appreciation of Patricia Katz, PhD and Edward Yelin, PhD, Co-Editors, Arthritis Care & Research, 2005-2011. Arthritis Care and Research, 2011, 63, 787-787.	3.4	0
250	Suppression of autoimmunity and organ pathology in lupusâ€prone mice upon inhibition of calcium/calmodulinâ€dependent protein kinase type IV. Arthritis and Rheumatism, 2011, 63, 523-529.	6.7	87
251	Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production. Arthritis and Rheumatism, 2011, 63, 503-512.	6.7	41
252	Calcium signaling in systemic lupus erythematosus T cells: A treatment target. Arthritis and Rheumatism, 2011, 63, 2058-2066.	6.7	61

#	Article	IF	Citations
253	Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis and Rheumatism, 2011, 63, 2755-2763.	6.7	36
254	cAMP-responsive Element Modulator (CREM)Î± Protein Induces Interleukin 17A Expression and Mediates Epigenetic Alterations at the Interleukin-17A Gene Locus in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 43437-43446.	3.4	122
255	Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Current Opinion in Rheumatology, 2011, 23, 449-453.	4.3	24
256	Induction of PP2A BÎ², a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12443-12448.	7.1	46
257	Cutting Edge: Calcium/Calmodulin-Dependent Protein Kinase Type IV Is Essential for Mesangial Cell Proliferation and Lupus Nephritis. Journal of Immunology, 2011, 187, 5500-5504.	0.8	66
258	Transcriptional Activation of the cAMP-responsive Modulator Promoter in Human T Cells Is Regulated by Protein Phosphatase 2A-mediated Dephosphorylation of SP-1 and Reflects Disease Activity in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 1795-1801.	3.4	55
259	A Novel Intronic cAMP Response Element Modulator (CREM) Promoter Is Regulated by Activator Protein-1 (AP-1) and Accounts for Altered Activation-induced CREM Expression in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 32366-32372.	3.4	28
260	Promoter Hypomethylation Results in Increased Expression of Protein Phosphatase 2A in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2011, 186, 4508-4517.	0.8	65
261	cAMP-responsive Element Modulator (CREM)Î± Protein Signaling Mediates Epigenetic Remodeling of the Human Interleukin-2 Gene. Journal of Biological Chemistry, 2011, 286, 43429-43436.	3.4	81
262	Pathogenesis of lupus. , 2011, , 1289-1294.e1.		1
263	Interleukin-17-producing T cells in lupus. Current Opinion in Rheumatology, 2010, 22, 499-503.	4.3	80
264	SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. Seminars in Immunopathology, 2010, 32, 157-171.	6.1	96
265	Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis and Rheumatism, 2010, 62, 1431-1437.	6.7	76
266	Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupusâ€prone mice. Arthritis and Rheumatism, 2010, 62, 2086-2092.	6.7	125
267	Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice. Arthritis and Rheumatism, 2010, 62, 2424-2431.	6.7	45
268	Alternative Splicing Factor/Splicing Factor 2 Regulates the Expression of the Î¶ Subunit of the Human T Cell Receptor-associated CD3 Complex. Journal of Biological Chemistry, 2010, 285, 12490-12496.	3.4	46
269	Cytokines in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-2.	3.0	2
270	IL-17 in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-4.	3.0	81

#	Article	IF	Citations
271	Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity, 2010, 43, 48-55.	2.6	42
272	Cutting Edge: IL-23 Receptor Deficiency Prevents the Development of Lupus Nephritis in C57BL/6â€˜lpr/lpr Mice. Journal of Immunology, 2010, 184, 4605-4609.	0.8	175
273	Lupus Serum IgG Induces Skin Inflammation through the TNFR1 Signaling Pathway. Journal of Immunology, 2010, 184, 7154-7161.	0.8	51
274	Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. American Journal of Physiology - Renal Physiology, 2010, 299, G391-G399.	3.4	45
275	Complement Receptor 1 Is a Sialic Acid-Independent Erythrocyte Receptor of Plasmodium falciparum. PLoS Pathogens, 2010, 6, e1000968.	4.7	86
276	The IL-2 Defect in Systemic Lupus Erythematosus Disease Has an Expansive Effect on Host Immunity. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	120
277	Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. Journal of Neuroinflammation, 2010, 7, 24.	7.2	31
278	Dendritic cell function in lupus: Independent contributors or victims of aberrant immune regulation. Autoimmunity, 2010, 43, 121-130.	2.6	34
279	T cells as therapeutic targets in SLE. Nature Reviews Rheumatology, 2010, 6, 317-325.	8.0	230
280	Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in Molecular Medicine, 2010, 16, 47-57.	6.7	311
281	Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Research and Therapy, 2010, 12, 222.	3.5	65
282	Is there a link between dysregulated miRNA expression and disease?. Discovery Medicine, 2010, 10, 184-94.	0.5	33
283	Mechanisms of Immune Complexâ€“Mediated Neutrophil Recruitment and Tissue Injury. Circulation, 2009, 120, 2012-2024.	1.6	171
284	The Cyclic AMP Response Element Modulator Î± Suppresses CD86 Expression and APC Function. Journal of Immunology, 2009, 182, 4167-4174.	0.8	25
285	Methylation Status of CpG Islands Flanking a cAMP Response Element Motif on the Protein Phosphatase 2AcÎ± Promoter Determines CREB Binding and Activity. Journal of Immunology, 2009, 182, 1500-1508.	0.8	70
286	Pathogenic Natural Antibodies Recognizing Annexin IV Are Required to Develop Intestinal Ischemia-Reperfusion Injury. Journal of Immunology, 2009, 182, 5363-5373.	0.8	116
287	Ischemia-mediated aggregation of the actin cytoskeleton is one of the major initial events resulting in ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2009, 296, G339-G347.	3.4	24
288	The Role of IL-23/IL-17 Axis in Lupus Nephritis. Journal of Immunology, 2009, 183, 3160-3169.	0.8	268

#	Article	IF	Citations
289	Human TCR-Î±Î²+ CD4â^' CD8â^' T Cells Can Derive from CD8+ T Cells and Display an Inflammatory Effector Phenotype. Journal of Immunology, 2009, 183, 4675-4681.	0.8	154
290	Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmunity Reviews, 2009, 8, 190-195.	5.8	89
291	IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clinical Immunology, 2009, 130, 313-321.	3.2	77
292	The Role of Complement in the Antiphospholipid Syndrome-Associated Pathology. Clinical Reviews in Allergy and Immunology, 2009, 36, 141-144.	6.5	12
293	B cells contribute to ischemia/reperfusion-mediated tissue injury. Journal of Autoimmunity, 2009, 32, 195-200.	6.5	39
294	Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation. Arthritis and Rheumatism, 2008, 58, 1216-1219.	6.7	11
295	Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2008, 7, 256-261.	5.8	41
296	Common variable immune deficiency (CVID) presenting as an autoimmune disease: role of memory B cells. Autoimmunity Reviews, 2008, 7, 309-312.	5.8	30
297	Sa.5. The Role of Lipid Rafts in the Pathogenesis of Systemic Lupus Erythematosus. Clinical Immunology, 2008, 127, S81.	3.2	0
298	Sa.45. Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2) Regulates the Expression of T Cell Receptor Î¶ chain. Clinical Immunology, 2008, 127, S95.	3.2	0
299	Sa.99. CREB Binds to Demethylated CRE-elements on the PP2AcÎ± Promoter and Induces Its Expression. Clinical Immunology, 2008, 127, S113.	3.2	0
300	T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clinical Immunology, 2008, 128, 1-7.	3.2	34
301	Complement Component C5a Mediates Hemorrhage-Induced Intestinal Damage. Journal of Surgical Research, 2008, 150, 196-203.	1.6	22
302	How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends in Immunology, 2008, 29, 110-115.	6.8	91
303	Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys. Journal of Immunology, 2008, 181, 8761-8766.	0.8	678
304	Differential Expression and Molecular Associations of Syk in Systemic Lupus Erythematosus T Cells. Journal of Immunology, 2008, 181, 8145-8152.	0.8	97
305	The RNA-stabilizing Protein HuR Regulates the Expression of Î¶ Chain of the Human T Cell Receptor-associated CD3 Complex. Journal of Biological Chemistry, 2008, 283, 20037-20044.	3.4	36
306	Cholera Toxin B Accelerates Disease Progression in Lupus-Prone Mice by Promoting Lipid Raft Aggregation. Journal of Immunology, 2008, 181, 4019-4026.	0.8	95

#	Article	IF	Citations
307	PP2A Dephosphorylates Elf-1 and Determines the Expression of CD3Î¶ and FcRÎ³ in Human Systemic Lupus Erythematosus T Cells. Journal of Immunology, 2008, 181, 3658-3664.	0.8	52
308	CTLAâ€4 expression regulation and its functions in systemic lupus erythematosus (SLE). FASEB Journal, 2008, 22, 667.9.	0.5	0
309	Phosphorylated ERM Is Responsible for Increased T Cell Polarization, Adhesion, and Migration in Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2007, 178, 1938-1947.	0.8	169
310	Increased Levels of NF-ATc2 Differentially Regulate CD154 and IL-2 Genes in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2007, 178, 1960-1966.	0.8	79
311	Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter. Journal of Immunology, 2007, 179, 3831-3840.	0.8	94
312	Systemic lupus erythematosus: new molecular targets. Annals of the Rheumatic Diseases, 2007, 66, iii65-iii69.	0.9	22
313	Anti-ribonucleoprotein antibodies mediate enhanced lung injury following mesenteric ischemia/reperfusion inRag-1â^'/â^'mice. Autoimmunity, 2007, 40, 208-216.	2.6	22
314	NEPHRITIC FACTOR AUTOANTIBODIES. , 2007, , 561-566.		0
315	C5-blocking antibody reduces fluid requirements and improves responsiveness to fluid infusion in hemorrhagic shock managed with hypotensive resuscitation. Journal of Applied Physiology, 2007, 102, 673-680.	2.5	17
316	Androstenediol inhibits the trauma-hemorrhage-induced increase in caspase-3 by downregulating the inducible nitric oxide synthase pathway. Journal of Applied Physiology, 2007, 102, 933-941.	2.5	21
317	C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine, 2007, 25, 7732-7736.	3.8	22
318	FcRÎ³ chain does not replace CD3Î¶ chain in CD3Î¶-deficient T lymphocytes of patients with gastric adenocarcinoma. Molecular Immunology, 2007, 44, 2400-2405.	2.2	4
319	Elf-1 Binds to GGAA Elements on the FcRÎ³ Promoter and Represses Its Expression. Journal of Immunology, 2007, 179, 4884-4889.	0.8	13
320	Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity, 2007, 40, 1-8.	2.6	80
321	Overview of the Pathogenesis of Systemic Lupus Erythematosus. , 2007, , 55-63.		2
322	Geldanamycin inhibits hemorrhage-induced increases in caspase-3 activity: role of inducible nitric oxide synthase. Journal of Applied Physiology, 2007, 103, 1045-1055.	2.5	17
323	2006 clinical immunology school on systemic autoimmune diseases. Autoimmunity Reviews, 2007, 6, 203.	5.8	0
324	Anti-RNP immunity: Implications for tissue injury and the pathogenesis of connective tissue disease. Autoimmunity Reviews, 2007, 6, 232-236.	5.8	35

#	Article	IF	Citations
325	Post-Transcriptional Regulation of T Cell Receptor zeta Chain in Systemic Lupus Erythematosus. Clinical Immunology, 2007, 123, S66.	3.2	2
326	Decay-accelerating factor attenuates remote ischemiaâ€“reperfusion-initiated organ damage. Clinical Immunology, 2007, 124, 311-327.	3.2	30
327	Syk kinase as a treatment target for therapy in autoimmune diseases. Clinical Immunology, 2007, 124, 235-237.	3.2	35
328	Proximal signaling control of human effector CD4 T cell function. Clinical Immunology, 2007, 125, 5-15.	3.2	7
329	Pathology and immunology of lupus glomerulonephritis: can we bridge the two?. International Urology and Nephrology, 2007, 39, 223-231.	1.4	7
330	Systemic lupus erythematosus: From disease pathogenesis to therapy. Drug Discovery Today Disease Mechanisms, 2006, 3, 185-192.	0.8	7
331	Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity, 2006, 39, 705-709.	2.6	45
332	Autoimmunity in systemic lupus erythematosus: Integrating genes and biology. Seminars in Immunology, 2006, 18, 230-243.	5.6	37
333	Systemic Lupus Erythematosus: New Ideas for Diagnosis and Treatment. , 2006, , 249-270.		0
334	Fas (CD95) ligation inhibits activation of NF-Î²B by targeting p65-Rel A in a caspase-dependent manner. Clinical Immunology, 2006, 121, 47-53.	3.2	6
335	Complement 3d: From molecular adjuvant to target of immune escape mechanisms. Clinical Immunology, 2006, 121, 177-185.	3.2	54
336	Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. Autoimmunity Reviews, 2006, 5, 118-121.	5.8	42
337	Complement, natural antibodies, autoantibodies and tissue injury. Autoimmunity Reviews, 2006, 5, 89-92.	5.8	77
338	Geldanamycin prevents hemorrhage-induced ATP loss by overexpressing inducible HSP70 and activating pyruvate dehydrogenase. American Journal of Physiology - Renal Physiology, 2006, 291, G117-G127.	3.4	20
339	In the Beginning Was Sm. Journal of Immunology, 2006, 176, 1295-1296.	0.8	14
340	Stability and Translation of TCR Î¶ mRNA Are Regulated by the Adenosine-Uridine-Rich Elements in Splice-Deleted 3â€² Untranslated Region of Î¶-Chain. Journal of Immunology, 2006, 177, 8248-8257.	0.8	17
341	The Transcriptional Repressor cAMP Response Element Modulator Î± Interacts with Histone Deacetylase 1 to Repress Promoter Activity. Journal of Immunology, 2006, 177, 6159-6164.	0.8	60
342	Complement in autoimmunity and tissue injury. Autoimmunity, 2006, 39, 355-356.	2.6	1

#	Article	IF	Citations
343	Animal Models of Autoimmune Disease. , 2006, , 329-348.		1
344	Immune cells and cytokines in systemic lupus erythematosus: an update. Current Opinion in Rheumatology, 2005, 17, 518-522.	4.3	80
345	Systemic lupus erythematosus and Sj??gren??s syndrome. Current Opinion in Rheumatology, 2005, 17, 511-512.	4.3	2
346	Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Current Opinion in Rheumatology, 2005, 17, 550-557.	4.3	136
347	Resuscitation with lactated Ringer solution limits the expression of molecular events associated with lung injury after hemorrhage. Journal of Applied Physiology, 2005, 98, 550-556.	2.5	17
348	Immune Cell Signaling and Gene Transcription in Human Systemic Lupus Erythematosus. , 2005, , 263-278.		1
349	Defective CD3Î¶ chain expression in Herpesvirus saimiri (HVS)-derived T-cell lines in gastric adenocarcinoma. Cellular Immunology, 2005, 238, 113-122.	3.0	8
350	New insights into the pathogenesis of systemic lupus erythematosus. Current Rheumatology Reports, 2005, 7, 469-475.	4.7	25
351	Gene Therapy in Systemic Lupus Erythematosus. Current Gene Therapy, 2005, 5, 677-684.	2.0	6
352	The Cyclic AMP Response Element Modulator Regulates Transcription of the TCR Î¶-Chain. Journal of Immunology, 2005, 175, 5975-5980.	0.8	44
353	Decreased Stability and Translation of T Cell Receptor Î¶ mRNA with an Alternatively Spliced 3â€²-Untranslated Region Contribute to Î¶ Chain Down-regulation in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2005, 280, 18959-18966.	3.4	68
354	C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. International Immunology, 2005, 17, 245-255.	4.0	37
355	Increased Caspase-3 Expression and Activity Contribute to Reduced CD3Î¶ Expression in Systemic Lupus Erythematosus T Cells. Journal of Immunology, 2005, 175, 3417-3423.	0.8	67
356	T cell-to-T cell clustering enhances NF-ÎºB activity by a PI3K signal mediated by Cbl-b and Rho. Biochemical and Biophysical Research Communications, 2005, 332, 1133-1139.	2.1	8
357	Intravenous immunoglobulin attenuates mesenteric ischemiaâ€“reperfusion injury. Clinical Immunology, 2005, 114, 137-146.	3.2	24
358	Monoclonal antibodies and fusion proteins in medicine. Journal of Allergy and Clinical Immunology, 2005, 116, 721-729.	2.9	34
359	Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. Journal of Clinical Investigation, 2005, 115, 996-1005.	8.2	109
360	Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. Journal of Clinical Investigation, 2005, 115, 996-1005.	8.2	199

#	Article	IF	Citations
361	Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. Journal of Clinical Investigation, 2005, 115, 3193-3204.	8.2	134
362	Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. Journal of Clinical Investigation, 2005, 115, 2444-2453.	8.2	153
363	Regulation of Complement Receptor Gene Expression. , 2004, , 61-73.		0
364	Overview of cellular immune function in systemic lupus erythematosus. , 2004, , 29-92.		7
365	B Cells, Be Gone â€" B-Cell Depletion in the Treatment of Rheumatoid Arthritis. New England Journal of Medicine, 2004, 350, 2546-2548.	27.0	76
366	IMMUNE CELL SIGNALING AND GENE TRANSCRIPTION IN HUMAN LUPUS: THE TIME HAS COME. International Reviews of Immunology, 2004, 23, 221-224.	3.3	2
367	TRANSCRIPTIONAL REGULATION OF INTERLEKIN 2 IN SLE T CELLS. International Reviews of Immunology, 2004, 23, 333-345.	3.3	29
368	Down-Regulation of IL-2 Production in T Lymphocytes by Phosphorylated Protein Kinase A-RIIÎ². Journal of Immunology, 2004, 172, 7804-7812.	0.8	14
369	Cyclic Adenosine 5â€²-Monophosphate Response Element Modulator Is Responsible for the Decreased Expression of c-fos and Activator Protein-1 Binding in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2004, 173, 3557-3563.	0.8	74
370	Accelerated Ischemia/Reperfusion-Induced Injury in Autoimmunity-Prone Mice. Journal of Immunology, 2004, 173, 4230-4235.	0.8	49
371	Neuroendocrine Aspects of Chronic Fatigue Syndrome. NeuroImmunoModulation, 2004, 11, 65-74.	1.8	40
372	Alterations in Lipid Raft Composition and Dynamics Contribute to Abnormal T Cell Responses in Systemic Lupus Erythematosus. Journal of Immunology, 2004, 172, 7821-7831.	0.8	172
373	Anti-Phospholipid Antibodies Restore Mesenteric Ischemia/Reperfusion-Induced Injury in Complement Receptor 2/Complement Receptor 1-Deficient Mice. Journal of Immunology, 2004, 173, 7055-7061.	0.8	84
374	TCR Î¶-Chain Abnormalities in Human Systemic Lupus Erythematosus. , 2004, 102, 049-072.		9
375	Role of Complement in Intestinal Ischemia/Reperfusion Induced Injury. , 2004, , 437-449.		0
376	Complement and Autoimmunity. , 2004, , 307-314.		0
377	Exploring complement activation to develop biomarkers for systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 3404-3407.	6.7	13
378	DISSECTING THE MOLECULAR MECHANISMS OF TCR Î¶ CHAIN DOWNREGULATION AND T Cell SIGNALING ABNORMALITIES IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS. International Reviews of Immunology, 2004, 23, 245-263.	3.3	11

#	Article	IF	Citations
379	T lymphocytes in systemic lupus erythematosus: an update. Current Opinion in Rheumatology, 2004, 16, 548-552.	4.3	39
380	SLE and SjÃ¶gren syndrome in 2004. Current Opinion in Rheumatology, 2004, 16, 497-498.	4.3	0
381	Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70. Journal of Applied Physiology, 2004, 97, 564-569.	2.5	50
382	OVERVIEW OF CELLULAR IMMUNE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2004, , 29-92.		12
383	NaCN-induced chemical hypoxia is associated with altered gene expression. Molecular and Cellular Biochemistry, 2003, 254, 211-216.	3.1	20
384	Constitutive NO synthase regulates the Na+/Ca2+ exchanger in human T cells: Role of [Ca2+]i and tyrosine phosphorylation. Journal of Cellular Biochemistry, 2003, 89, 1030-1043.	2.6	19
385	Reconstitution of deficient T cell receptor ? chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 1948-1955.	6.7	103
386	Activation of the Ets Transcription Factor Elfâ€1 Requires Phosphorylation and Glycosylation. Annals of the New York Academy of Sciences, 2003, 987, 240-245.	3.8	38
387	Human c1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. Journal of Surgical Research, 2003, 115, 247-256.	1.6	39
388	Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends in Immunology, 2003, 24, 259-263.	6.8	104
389	C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusionâ˜†â˜†The opinions contained herein are the private ones of the authors and are not to be construed as official policy or reflecting the views of the Department of Defense.. Clinical Immunology, 2003, 106, 55-64.	3.2	35
390	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injuryâ˜†,â˜†â˜†. Clinical Immunology, 2003, 108, 263-273.	3.2	53
391	Uncovering the Genetics of Systemic Lupus Erythematosus. Molecular Diagnosis and Therapy, 2003, 3, 193-202.	3.3	5
392	T Cell Rewiring in Differentiation and Disease. Journal of Immunology, 2003, 171, 3325-3331.	0.8	57
393	The Cyclic Adenosine 5â€²-Monophosphate Response Element Modulator Suppresses IL-2 Production in Stimulated T Cells by a Chromatin-Dependent Mechanism. Journal of Immunology, 2003, 170, 2971-2976.	0.8	75
394	Protein Kinase A Regulatory Subunit Type IIÎ² Directly Interacts with and Suppresses CREB Transcriptional Activity in Activated T Cells. Journal of Immunology, 2003, 171, 3636-3644.	0.8	28
395	The FcRÎ³ Subunit and Syk Kinase Replace the CD3Î¶-Chain and ZAP-70 Kinase in the TCR Signaling Complex of Human Effector CD4 T Cells. Journal of Immunology, 2003, 170, 4189-4195.	0.8	113
396	Forced Expression of the Fc Receptor Î³-Chain Renders Human T Cells Hyperresponsive to TCR/CD3 Stimulation. Journal of Immunology, 2003, 170, 2871-2876.	0.8	42

#	Article	IF	Citations
397	Transcriptional Activation of the Human Inducible Nitric-oxide Synthase Promoter by KrÃ¼ppel-like Factor 6. Journal of Biological Chemistry, 2003, 278, 14812-14819.	3.4	71
398	Autoimmunity, Complement Activation, Tissue Injury and Reciprocal Effects. , 2003, 7, 149-164.		27
399	T cell abnormalities in human and mouse lupus: intrinsic and extrinsic. Current Opinion in Rheumatology, 2003, 15, 542-547.	4.3	39
400	The TRAIL to arthritis. Journal of Clinical Investigation, 2003, 112, 1315-1317.	8.2	18
401	The TRAIL to arthritis. Journal of Clinical Investigation, 2003, 112, 1315-1317.	8.2	6
402	Mice Deficient in Complement Receptors 1 and 2 Lack a Tissue Injury-Inducing Subset of the Natural Antibody Repertoire. Journal of Immunology, 2002, 169, 2126-2133.	0.8	165
403	Phosphorylation and O-Linked Glycosylation of Elf-1 Leads to Its Translocation to the Nucleus and Binding to the Promoter of the TCR Î¶-Chain. Journal of Immunology, 2002, 168, 2865-2871.	0.8	72
404	NF-ÎºB Regulates the Expression of the Human Complement Receptor 2 Gene. Journal of Immunology, 2002, 169, 6236-6243.	0.8	27
405	Antisense Cyclic Adenosine 5â€²-Monophosphate Response Element Modulator Up-Regulates IL-2 in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2002, 169, 4147-4152.	0.8	93
406	N Ï‰-nitro-l-arginine inhibits inducible HSP-70 via Ca2+, PKC, and PKA in human intestinal epithelial T84 cells. American Journal of Physiology - Renal Physiology, 2002, 282, G415-G423.	3.4	14
407	Protein kinase A enhances, whereas glycogen synthase kinase-3Î² inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion. Biochemical Journal, 2002, 363, 127.	3.7	22
408	Protein kinase A enhances, whereas glycogen synthase kinase-3Î² inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion. Biochemical Journal, 2002, 363, 127-136.	3.7	22
409	Heat stress protection against mesenteric I/R-induced alterations in intestinal mucosa in rats. Journal of Applied Physiology, 2002, 92, 2600-2607.	2.5	28
410	Diabetic Hyperglycemia: A Facilitating Factor in Systemic Capillary Leak. Journal of Surgical Research, 2002, 105, 95-101.	1.6	10
411	Direct Transfer of p65 into T Lymphocytes from Systemic Lupus Erythematosus Patients Leads to Increased Levels of Interleukin-2 Promoter Activity. Clinical Immunology, 2002, 103, 145-153.	3.2	45
412	The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR. Journal of Biological Chemistry, 2002, 277, 14942-14953.	3.4	50
413	Abnormal B Cell Signal Transduction in Systemic Lupus Erythematosus. , 2002, 6, 89-104.		15
414	Oxidative stress is involved in the heat stress-induced downregulation of TCR Î¶ chain expression and TCR/CD3-mediated [Ca2+]i response in human T-lymphocytes. Cellular Immunology, 2002, 215, 151-161.	3.0	19

#	Article	IF	Citations
415	Abnormal expression of various molecular forms and distribution of T cell receptor ? chain in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2002, 46, 163-174.	6.7	58
416	Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis and Rheumatism, 2002, 46, 1139-1154.	6.7	141
417	Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: A new mechanism for TCR ? chain deficiency and abnormal signaling. Journal of Cellular Biochemistry, 2002, 85, 459-469.	2.6	39
418	Polymorphisms/Mutations of TCR-Î¶-Chain Promoter and 3â€² Untranslated Region and Selective Expression of TCR Î¶-Chain with an Alternatively Spliced 3â€² Untranslated Region in Patients with Systemic Lupus Erythematosus. Journal of Autoimmunity, 2001, 16, 133-142.	6.5	71
419	Defective FcÎ³RIIb1 Signaling Contributes to Enhanced Calcium Response in B Cells from Patients with Systemic Lupus Erythematosus. Clinical Immunology, 2001, 101, 130-135.	3.2	70
420	A disease with a complex pathogenesis. Lancet, The, 2001, 358, S65.	13.7	22
421	IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN HUMAN MEMORY (CD45RO+) CD4+T LYMPHOCYTES. Immunological Investigations, 2001, 30, 87-101.	2.0	5
422	Abnormal T Lymphocyte Signal Transduction in Systemic Lupus Erythematosus. , 2001, 5, 131-150.		14
423	Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3Î¶ expression. Blood, 2001, 97, 3851-3859.	1.4	67
424	High dose of dexamethasone upregulates TCR/CD3-induced calcium response independent of TCR ? chain expression in human T lymphocytes. Journal of Cellular Biochemistry, 2001, 83, 401-413.	2.6	11
425	Fc? receptor type I ? chain replaces the deficient T cell receptor ? chain in T cells of patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2001, 44, 1114-1121.	6.7	158
426	T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor ? chain messenger RNA. Arthritis and Rheumatism, 2001, 44, 1336-1350.	6.7	67
427	Dexamethasone Modulates TCR Î¶ Chain Expression and Antigen Receptor-Mediated Early Signaling Events in Human T Lymphocytes. Cellular Immunology, 2001, 208, 62-71.	3.0	24
428	Multiple Transcription Factors Regulate the Inducible Expression of the Human Complement Receptor 2 Promoter. Journal of Immunology, 2001, 166, 6156-6163.	0.8	25
429	Protein Kinase C-Î¸ Participates in the Activation of Cyclic AMP-Responsive Element-Binding Protein and Its Subsequent Binding to the â^'180 Site of the IL-2 Promoter in Normal Human T Lymphocytes. Journal of Immunology, 2001, 166, 5665-5674.	0.8	56
430	Complement Inhibitor, Complement Receptor 1-Related Gene/Protein y-Ig Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice. Journal of Immunology, 2001, 167, 5921-5927.	0.8	75
431	ZAP-70 and SLP-76 Regulate Protein Kinase C-Î¸ and NF-ÎºB Activation in Response to Engagement of CD3 and CD28. Journal of Immunology, 2001, 166, 5654-5664.	0.8	70
432	Molecular Basis of Deficient IL-2 Production in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2001, 166, 4216-4222.	0.8	188

#	Article	IF	Citations
433	FcÎµ receptor type I Î³ chain replaces the deficient T cell receptor Î¶ chain in T cells of patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2001, 44, 1114-1121.	6.7	2
434	The Clinical Spectrum of Anti-Insulin Receptor Antibodies and Autoimmune Disease. Journal of Clinical Rheumatology, 2001, 7, 361-362.	0.9	0
435	Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. Biochemical Journal, 2000, 348, 151.	3.7	8
436	Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. Biochemical Journal, 2000, 348, 151-158.	3.7	32
437	Immune cell signaling in lupus. Current Opinion in Rheumatology, 2000, 12, 355-363.	4.3	59
438	Heat stress downregulates TCR ? chain expression in human T lymphocytes. Journal of Cellular Biochemistry, 2000, 79, 416-426.	2.6	15
439	Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350. European Journal of Immunology, 2000, 30, 969-973.	2.9	13
440	Molecular aberrations in human systemic lupus erythematosus. Trends in Molecular Medicine, 2000, 6, 418-424.	2.6	63
441	Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. Journal of Clinical Immunology, 2000, 20, 1-9.	3.8	16
442	Regulation of heat shock protein 72 kDa and 90 kDa in human breast cancer MDA-MB-231 cells. Molecular and Cellular Biochemistry, 2000, 204, 169-178.	3.1	29
443	Association of Deficient Type II Protein Kinase A Activity with Aberrant Nuclear Translocation of the RIIÎ² Subunit in Systemic Lupus Erythematosus T Lymphocytes. Journal of Immunology, 2000, 165, 2830-2840.	0.8	39
444	Serum Regulates the Expression of Complement Receptor 2 on Human B Cell Lines. Immunopharmacology and Immunotoxicology, 2000, 22, 205-219.	2.4	2
445	Inhibition of ischemia reperfusion-induced intestinal injury and systemic inflammation by a novel complement regulatory protein. Gastroenterology, 2000, 118, A829.	1.3	0
446	Role of HSP70I in heat stress and glutamine protection against mesenteric ischemia/reperfusion (IR)-induced injury in vivo. Gastroenterology, 2000, 118, A1123.	1.3	0
447	Gene therapy in the treatment of autoimmune diseases. Journal of Clinical Investigation, 2000, 106, 181-183.	8.2	30
448	Characterization of Distinct Heat Shock- and ThapsigarginInduced Cytoprotective Proteins in FRTL-5 Thyroid Cells. Thyroid, 1999, 9, 1041-1047.	4.5	2
449	Immune cell signaling defects in lupus: activation, anergy and death. Trends in Immunology, 1999, 20, 119-124.	7.5	108
450	Biochemical requirements for the expression of heat shock protein 72 kda in human breast cancer MCF-7 cells. Molecular and Cellular Biochemistry, 1999, 199, 179-188.	3.1	17

#	Article	IF	Citations
451	Antiinflammatory Effects of Soluble Complement Receptor Type 1 Promote Rapid Recovery of Ischemia/Reperfusion Injury in Rat Small Intestine. Clinical Immunology, 1999, 90, 266-275.	3.2	61
452	Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specificDNA-binding protein. Biochemical Journal, 1999, 338, 417-425.	3.7	43
453	Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specificDNA-binding protein. Biochemical Journal, 1999, 338, 417.	3.7	14
454	B Cells in Systemic Lupus Erythematosus. , 1999, , 167-180.		3
455	The Alter Ego of Heat Shock Proteins. Clinical Immunology and Immunopathology, 1998, 86, 235-236.	2.0	2
456	Complement Receptor 2 in the Regulation of the Immune Response. Clinical Immunology and Immunopathology, 1998, 88, 123-132.	2.0	35
457	Abnormal Early TCR/CD3-Mediated Signaling Events of a snRNP-Autoreactive Lupus T Cell Clone. Clinical Immunology and Immunopathology, 1998, 88, 305-310.	2.0	22
458	Corticotropin-releasing factor induces phosphorylation of phospholipase C-Î³ at tyrosine residues via its receptor 2Î² in human epidermoid A-431 cells. European Journal of Pharmacology, 1998, 363, 203-210.	3.5	10
459	Heat Shock Protein 70 kDa Molecular Biology, Biochemistry, and Physiology. , 1998, 80, 183-201.		1,010
460	Immune cell signaling aberrations in human lupus. Immunologic Research, 1998, 18, 27-39.	2.9	23
461	Lymphocytes, cytokines, inflammation, and immune trafficking. Current Opinion in Rheumatology, 1998, 10, 417-425.	4.3	29
462	Cytoprotection and regulation of heat shock proteins induced by heat shock in human breast cancer T47â€Ð cells: role of [Ca 2+] i and protein kinases. FASEB Journal, 1998, 12, 1571-1579.	0.5	24
463	Overexpression of HSPâ€70 inhibits the phosphorylation of HSF1 by activating protein phosphatase and inhibiting protein kinase C activity. FASEB Journal, 1998, 12, 451-459.	0.5	84
464	Lymphocytes, cytokines, inflammation, and immune trafficking. Current Opinion in Rheumatology, 1997, 9, 380-386.	4.3	23
465	Heat-Shock of Normal T-Cells and T-Cell Lines Downregulates the TCR/CD3-Mediated Cytoplasmic CA2+Responses and the Production of Inositol Triphosphate. Immunopharmacology and Immunotoxicology, 1997, 19, 511-521.	2.4	4
466	Increased Expression of Functional Fas-Ligand in Activated T Cells from Patients with Systemic Lupus Erythematosus. Autoimmunity, 1997, 25, 213-221.	2.6	61
467	Gammalinolenic Acid and Dihomogammalinolenic Acid Suppress the CD3-Mediated Signal Transduction Pathway in Human T Cells. Clinical Immunology and Immunopathology, 1997, 83, 237-244.	2.0	28
468	Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis and Rheumatism, 1997, 40, 980-982.	6.7	37

#	Article	IF	Citations
469	Modulation of Human T-Lymphocyte Plasma Membrane Ca +2 Permeability by Imidazole Antimycotics. Immunopharmacology and Immunotoxicology, 1996, 18, 237-245.	2.4	9
470	Cell signaling and heat shock protein expression. Journal of Biomedical Science, 1996, 3, 379-388.	7.0	15
471	Defective CD3-Mediated Cell Death in Activated T Cells from Patients with Systemic Lupus Erythematosus: Role of Decreased Intracellular TNF-Î±. Clinical Immunology and Immunopathology, 1996, 81, 293-302.	2.0	102
472	Defective antigen-presenting cell function in patients with systemic lupus erythematosus: Role of the B7-1 (CD80) costimulatory molecule. Arthritis and Rheumatism, 1996, 39, 600-609.	6.7	57
473	Nephritic Factor Autoantibodies. , 1996, , 540-545.		1
474	Cd28 expression on t cell subsets in vivo and cd28-mediated t cell response in vitro in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1995, 38, 649-654.	6.7	31
475	Effects of an aminosteroid inhibitor of phospholipase C-dependent processes on the TCR-mediated signal transduction pathway in human T cells. Clinical Immunology and Immunopathology, 1995, 77, 59-68.	2.0	11
476	Characterization of in Vivo Mutated T Cell Clones from Patients with Systemic Lupus Erythematosus. Clinical Immunology and Immunopathology, 1995, 74, 135-142.	2.0	37
477	Lymphocytes, cytokines, inflammation, and immune trafficking. Current Opinion in Rheumatology, 1994, 6, 461-467.	4.3	5
478	Elevated Soluble CD8 Antigen and Soluble Interleukin-2 Receptors in the Sera of Patients with Juvenile Rheumatoid Arthritis. Clinical Immunology and Immunopathology, 1993, 68, 64-67.	2.0	17
479	Circulating Intercellular Adhesion Molecule-1 in Patients with Systemic Sclerosis. Clinical Immunology and Immunopathology, 1993, 68, 88-92.	2.0	65
480	Immunohistological Demonstration of Transforming Growth Factor-Î² Isoforms in the Skin of Patients with Systemic Sclerosis. Clinical Immunology and Immunopathology, 1993, 69, 199-204.	2.0	58
481	Nucleotide Sequence of a Human Autoantibody to the Alternative Pathway C3/C5 Convertase (C3NeF). Hybridoma, 1993, 12, 231-237.	0.6	9
482	Pathogenesis of human systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1992, 63, 3.	2.0	6
483	Study of the idiotypic response to autoantibody to the alternative pathway convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals. Clinical Immunology and Immunopathology, 1992, 62, 291-294.	2.0	7
484	On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): Evidence for the Adam and Eve concept of autoantibody production. Clinical Immunology and Immunopathology, 1992, 64, 177-183.	2.0	21
485	Cholera toxin promotes the proliferation of anti-Î¼ antibody-prestimulated human B cells. Cellular Immunology, 1992, 140, 237-247.	3.0	8
486	Kinetics of interleukin-4 induction and interferon-Î³ inhibition of IgE secretion by Epstein-Barr virus-infected human peripheral blood B cells. Cellular Immunology, 1991, 133, 408-419.	3.0	9

#	Article	IF	Citations
487	Immune Abnormalities in the Pathogenesis of Juvenile Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 1991, 17, 843-857.	1.9	11
488	The CR2 receptor (CD21) shows increased expression in the more differentiated cells of an antigen-specific B cell line. Cellular Immunology, 1990, 125, 386-395.	3.0	3
489	C-MYC proto-oncogene expression in peripheral blood mononuclear cells from patients with primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 1990, 33, 49-56.	6.7	11
490	Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. International Immunology, 1990, 2, 651-659.	4.0	61
491	Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. Journal of Pediatrics, 1990, 116, S103-S108.	1.8	30
492	Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clinical Immunology and Immunopathology, 1990, 57, 10-18.	2.0	23
493	Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase. Clinical Immunology and Immunopathology, 1990, 57, 19-31.	2.0	17
494	Human polyclonal and monoclonal IgG and IgM complement 3 nephritic factors: Evidence for idiotypic commonality. Clinical Immunology and Immunopathology, 1989, 53, 113-122.	2.0	12
495	Transcriptional and post-transcriptional mechanisms are responsible for the increased expression of c-myc protooncogene in lymphocytes from patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1989, 52, 507-515.	2.0	14
496	Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway. Clinical Immunology and Immunopathology, 1988, 46, 91-99.	2.0	10
497	Immunoregulatory aberrations in patients with polyarticular juvenile rheumatoid arthritis. Clinical Immunology and Immunopathology, 1988, 47, 62-74.	2.0	20
498	Mood effects of alternate-day corticosteroid therapy in patients with systemic lupus erythematosus. General Hospital Psychiatry, 1988, 10, 56-60.	2.4	18
499	A Factor Activating Complement via the Alternative Pathway in the Supernatants of B Cell Lines Transformed by Epstein-Barr Virus and in Sera Obtained from Patients with Systemic Lupus erythematosus. International Archives of Allergy and Immunology, 1988, 86, 209-214.	2.1	4
500	Alternate-Day Corticosteroid Treatment, Mood and Plasma HVA in Patients with Systemic Lupus erythematosus. Neuropsychobiology, 1988, 19, 17-19.	1.9	3
501	Dissociation between Cortisol and Adrenal Androgen Secretion in Patients Receiving Alternate Day Prednisone Therapy. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 24-29.	3.6	34
502	Cellular immunity in patients with systemic juvenile rheumatoid arthritis. Clinical Immunology and Immunopathology, 1987, 42, 86-92.	2.0	15
503	Rheumatic disease syndromes associated with antibodies to the Ro (SS-A) ribonuclear protein. Seminars in Arthritis and Rheumatism, 1987, 16, 237-244.	3.4	22
504	Immunomodulatory treatment in patients with rheumatic diseases: Mechanisms of action. Seminars in Arthritis and Rheumatism, 1987, 17, 24-38.	3.4	31

#	Article	IF	Citations
505	Development of hypogammaglobulinemia in a patient with systemic lupus erythematosus. American Journal of Medicine, 1986, 81, 1081-1084.	1.5	30
506	Regulation of Human Cytotoxic Responses by Complement: C3, C3b and C3d Preparations Enhance Human Allogeneic Cytotoxic Responses. Immunopharmacology and Immunotoxicology, 1986, 8, 529-541.	2.4	5
507	Deficient Î³-interferon production in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1986, 29, 1210-1215.	6.7	62
508	A clinical and pathologic study of cerebrovascular disease in patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 1986, 16, 70-78.	3.4	46
509	Treatment of Discoid Skin Lesions With Azathioprine-Reply. Archives of Dermatology, 1986, 122, 746.	1.4	0
510	Enhancement of Human Allogeneic Cytotoxic Responses by Interferons. Immunopharmacology and Immunotoxicology, 1985, 7, 403-415.	0.8	6
511	Lupus Nephritis and Other Autoimmune Features in Patients with Diabetes Mellitus Due to Autoantibody to Insulin Receptors. Annals of Internal Medicine, 1985, 102, 176.	3.9	39
512	Human T-cell leukemia/lymphoma virus I and/or Epstein-Barr virus-infected B-cell lines spontaneously produce acid-labile ?-interferon. Journal of Clinical Immunology, 1985, 5, 340-344.	3.8	12
513	Pituitary-Adrenal Responsiveness to Corticotropin-Releasing Hormone in Patients Receiving Chronic, Alternate Day Glucocorticoid Therapy*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 22-27.	3.6	55
514	Successful Treatment of Generalized Discoid Skin Lesions With Azathioprine. Archives of Dermatology, 1985, 121, 1323.	1.4	43
515	Immunosuppressive Agents and Plasmapheresis in Immunological Disorders. Immunopharmacology and Immunotoxicology, 1985, 7, 1-15.	0.8	12
516	Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1985, 34, 379-386.	2.0	30
517	Lymphocyte subpopulations in patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1984, 31, 181-190.	2.0	5
518	Induction of monocytic suppression after stimulation of peripheral human mononuclear cells with staphylococcal protein A and Staphylococcus aureus. Cellular Immunology, 1983, 78, 144-151.	3.0	6
519	Phenotypes of T lymphocytes in systemic lupus erythematosus: Decreased cytotoxic/suppressor subpopulation is associated with deficient allogeneic cytotoxic responses rather than with concanavalin A-induced suppressor cells. Clinical Immunology and Immunopathology, 1983, 26, 267-276.	2.0	19
520	Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1982, 24, 179-185.	2.0	23
521	Recovery of splenic function after gvhd-associated functional asplenia. American Journal of Hematology, 1982, 12, 77-80.	4.1	12
522	Suppressor cells generated from human peripheral mononuclear cells by stimulation with pokeweed mitogen. Cellular Immunology, 1981, 65, 221-229.	3.0	9

#	Article	IF	Citations
523	Spontaneous and pokeweed mitogen-induced plaque-forming cells in systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1981, 21, 172-183.	2.0	31
524	Renal and Metabolic Complications of Undifferentiated and Lymphoblastic Lymphomas. Medicine (United States), 1981, 60, 218-229.	1.0	143
525	Cytotoxic responses to alloantigens in systemic lupus erythematosus. Journal of Clinical Immunology, 1981, 1, 208-216.	3.8	15
526	Chlorpromazine and Lidocaine Inhibit Antibody-Dependent Cell-Mediated Cytotoxicity but Not Erythrocyte Antibody Rosette Formation. International Archives of Allergy and Immunology, 1980, 61, 344-346.	2.1	2
527	Inhibition of capping of immunoglobulin and concanavalin A receptors by cis-dichlorodiammineplatinum-(II) in mouse spleen cells. Cancer Letters, 1980, 10, 261-267.	7.2	6